TY - JOUR T1 - Novel Diffuse White Matter Abnormality Biomarker at Term-Equivalent Age Enhances Prediction of Long-term Motor Development in Children Born Very Preterm JF - medRxiv DO - 10.1101/2020.08.04.20167031 SP - 2020.08.04.20167031 AU - Nehal A. Parikh AU - Karen Harpster AU - Lili He AU - Venkata Sita Priyanka Illapani AU - Fatima Chughtai Khalid AU - Mark A. Klebanoff AU - T. Michael O’Shea AU - Mekibib Altaye Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/06/2020.08.04.20167031.abstract N2 - Our objective was to evaluate the independent prognostic value of a novel MRI biomarker – objectively diagnosed diffuse white matter abnormality volume (DWMA; diffuse excessive high signal intensity) – for prediction of motor outcomes in very preterm infants. We prospectively enrolled a geographically-based cohort of very preterm infants without severe brain injury and born before 32 weeks gestational age. Structural brain MRI was obtained at term-equivalent age and DWMA volume was objectively quantified using a published validated algorithm. These results were compared with visually classified DWMA. We used multivariable linear regression to assess the value of DWMA volume, independent of known predictors, to predict motor development as assessed using the Bayley Scales of Infant & Toddler Development, Third Edition at 3 years of age. The mean (SD) gestational age of the cohort was 28.3 (2.4) weeks. In multivariable analyses, controlling for gestational age, sex, and abnormality on structural MRI,DWMA volume was an independent prognostic biomarker of Bayley Motor scores (β= –12.59 [95% CI: –18.70, –6.48] R2=0.41). Conversely, visually classified DWMA was not predictive of motor development. In conclusion, objectively quantified DWMA is an independent prognostic biomarker of long-term motor development in very preterm infants and warrants further study.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by the National Institutes of Health (grants R01-NS094200 and R01-NS096037 [to NAP] and grant R21-HD094085 [to LH])Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Nationwide Children's Hospital (NCH) Institutional Review Board approved the study at NCH and the other study sites through established reciprocity agreements.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data, software, and code from this study can be accessed from the lead author upon request ER -